The liquid biopsy market is projected to experience significant growth between 2025 and 2035, The market is expected to reach approximately USD 3,640.9 million in 2025 and expand to around USD 19,708.5 million by 2035, reflecting a compound annual growth rate (CAGR) of 8.4% over the forecast period.
The growing burden of cancer on a global scale has created the need for early detection methods, as early diagnosis increases the success of treatment and contributes to improved survival. The conventional biopsy procedures, however, are time-consuming and invasive; moreover, they cannot be repeated on a regular basis.
There has therefore been a strong necessity for non-invasive methods. Liquid plasma biopsy has appeared as a powerful method for finding circulating tumor DNA and other bio-markers in a highly sensitive manner, including in early stages of cancer. This allows prompt intervention and patient-tailored treatment planning.
The growing preference towards cancer screening programs and breakthroughs in the liquid biopsy tools are making liquid biopsies universally accepted and hence plasma-based assays are being made a mandatory component of cutting-edge oncology diagnostics and personalized medicine.
Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 3,640.9 million |
| Industry Value (2035F) | USD 19,708.5 million |
| CAGR (2025 to 2035) | 8.4% |
From the development of the liquid biopsy market, there has been a definite demand for non-invasive cancer diagnostics and real-time disease monitoring in greater measure. Early on, the market barely crawled, with limited applications in clinical development because of doubts raised about liquid biopsy sensitivity and specificity. The arrival of NGS and ctDNA put forth the idea that liquid biopsy could be a more practical option compared to conventional tissue biopsy.
Progression in technology widened the horizon of liquid biopsy applications from oncology to prenatal testing, infections, and organ transplantation monitoring. An ever-increasing interest in the early detection of cancers and personalized medicine fueled the growth further.
Investments from pharmaceutical and diagnostic companies were higher for carrying out clinical validation studies, resulting in a wider spectrum of regulatory approvals and commercial availability of liquid biopsy assays. Innovation continued in this direction, maturing the market and accelerating the development of cheaper, faster, and more precise diagnostics, paving the way for even more extensive integration into routine clinical practice.
Explore FMI!
Book a free demo
As several high-end biotechnology organizations make their presence felt in North America, the country finds itself on the ways to a very promising multi-million dollar market in liquid biopsy. Market volume growth is driven by a huge increase in precision oncology; further investment in cancer research; and the establishment of regulatory infrastructures within member countries that continuously support the USA with favorable reimbursement policies, along with widespread availability of newly advanced sequencing technologies, and an increasing government push towards new funding for non-invasive cancer diagnostics.
The challenges of the market include complexity in reimbursement, consolidation in the standardization of liquid biopsy assays, and false-positive interpretations. From a strong movement towards multi-cancer early detection tests, application expansion plans for liquid biopsies into neurodegenerative and cardiovascular diseases, and incorporation of AI-powered data interpretation platforms, strong advancement is anticipated in the North American market.
Europe thus forms a significant market for liquid biopsy-aspects owing to increasing initiatives for cancer screening, increasing adoption of companion diagnostics in addition to strong support in regulations with indicator driven therapies. Major markets include countries such as Germany, France, and the UK Well-established structures, increasing participation in clinical trials, and improved implementation of precision medicine strategies are common in the three nations.
The market growth is susceptible to obstacles such as price limitations, slow integration of novel liquid biopsy tests in existing clinical practice, and different reimbursement policies among nations. Emerging trends in decentralized liquid biopsy testing, the extension of pan-European cancer biomarker research programs, and increasing collaborations of academic institutes with biotech companies are shaping the market landscape. Promoting integration of digital pathology with liquid biopsy platforms is also paving the way for improvements in cancer diagnosis and treatment monitoring.
A rapid rise in the Asia-Pacific liquid biopsy sector is attributed to soaring cancer burden, improving access to molecular diagnostics, and increasing investments in genomic medicine. Among this group of key markets, China, Japan, and India have expanding biotech R&D capabilities, increasing government support for cancer early detection programs, and exciting adoption of liquid biopsy techniques for treatment selection and disease monitoring.
However, some inhibitive barriers toward the penetration of the liquid biopsy market include affording limitations, lack of awareness among healthcare professionals, and very few available liquid biopsy tests in rural areas. The increasing presence of global biotech firms and a broadening precision oncology initiative further strengthen the growing use of liquid biopsy in countries' national cancer screening programs to drive market growth. In addition, advances in single-cell analytics and an increasing number of applications of liquid biopsy in monitoring responses to immunotherapy are improving personal cancer treatment outcomes in this region.
Challenges
Low Concentration of Tumor Biomarkers is Emerging as the Prominent Growth Barrier
A big challenge that concerns ctDNA and tumor-derived biomarkers in plasma samples of the plasma liquid biopsy is their low concentration. Some tumors shed DNA in the bloodstream in variable amounts, while with respect to early-stage cancers, ctDNA levels are often very low and may instead pose a challenge in detection.
The limited availability of tumor-derived genetic materials thus opens up chances for false negatives- and hence, missed diagnosis or delayed initiation of therapy. Additionally, a large background of normal cfDNA can dilute ctDNA, complicating matters in accurate analyses. Specialized techniques with higher sensitivity, requiring digital PCR and ultra-deep next-generation sequencing, are necessary for addressing this limitation, thereby increasing costs and technical complexity.
Opportunities
Advancement in ultra-sensitive detection technologies is reforming the plasma liquid biopsy market.
Advancements in ultra-sensitive detection technologies such as digital PCR, ultra-deep sequencing, and novel biomarker discovery are transforming the accuracy and reliability of plasma liquid biopsy. Digital PCR allows precise quantification of low-abundance circulating tumor DNA (ctDNA), resulting in substantially fewer false negatives for early stage cancers; ultra-deep sequencing also applies this technique in generating higher sensitivity mutation detection with the analysis of massive amounts of genetic data, thus also allowing small traces of tumor-derived DNA to be identified from plasma.
Moreover, ongoing investigations on novel biomarkers such as methylation patterns and extracellular vesicles widen the range of liquid biopsy applications. Collectively, these innovations render plasma-based assays more powerful in early cancer detection, the selection of therapy, and the monitoring of response.
As these technologies continue to evolve, their potential to enhance outcomes in diagnosis, enable earlier intervention, and personalize cancer care is phenomenal, thereby generating ever-increasing uptake of plasma liquid biopsy into clinical practice.
Advancements in Multi-Cancer Early Detection Technologies Is Propelling the Overall Market Growth
Advancements in multi-cancer early detection (MCED) technologies are profoundly changing the landscape of the liquid biopsy market by enabling the investigation of multiple cancer types through testing carried out on a single blood sample. Tumor-associated circulating DNA (ctDNA) and RNA with other types of markers are utilized for the diagnosis of early forms of cancers and intervention.
These interventions offer the patient the greatest chance for survival. The MCED assay provides an early detection that is much appreciated as non-invasive, user-friendly, and scalable, providing less chance of performing tissue biopsies or other invasive procedures.
NGS and methylation-based assay innovations are being continuously conducted to achieve improved test accuracy and sensitivity in the identification of tumor origins prior to the advent of clinical symptoms. There has emerged a growing interest in developing early cancer detection mechanisms as a means of reducing cancer-associated mortality, which in turn has helped to increase funding potential from research avenues and regulatory support.
As technologies gain validation within clinical settings, implementation into routine cancer screening programs is deemed to regenerate the whole sphere of oncology-related diagnostics worldwide.
Rising Adoption of Multi-Cancer Early Detection (MCED) Tests is Transforming Cancer Screening
The tests for Multi-Cancer Early Detection (MCED) are increasing with upcoming plasma liquid biopsy, and this is all going to change the landscape of cancer diagnostics-space itself, i.e., the possibility of detecting more than one type of cancer from a single blood sample. Indeed, standard cancer screening techniques test for single cancer types and offer no chance for early intervention in the event of screening positive.
MCED tests are advanced technologies relying on next-generation sequencing (NGS) and methylation-based assays to identify tumor-derived genetic and epigenetic alterations across diverse cancer types. Such tests provide early diagnosis, especially in asymptomatic and covert cancers, allowing for improved patient outcomes.
Rising incidence of cancer diseases coupled with the demand for less invasive diagnosis has made the liquid biopsy market grow manifold in the last few years. Next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis, and multi-cancer early detection (MCED) tests are the giants laying roadblocks to progress in cancer diagnostics from 2020 to 2024.
Liquid biopsy became one of the major tools to monitor a condition and personalize treatments, among other advantages, enabling it to become a faster and more patient-friendly replacement for conventional biopsies.
The layout for the period between 2025 and 2035 thus demands even greater development. A new generation of technologies in multi-omics and data analytics shall improve cancer detection and monitoring. Further, wider regulatory approvals and insurance coverage will aid liquid biopsy to cross the threshold into accessibility. Companies, therefore, will need to invest in assay standardization, build strong partnerships, and keep innovating to address new demands of cancer care, if they intend to keep being competitive.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Increasing approvals for liquid biopsy tests for cancer detection and treatment monitoring. |
| Technological Advancements | Adoption of ctDNA, CTC, and exosome-based liquid biopsy techniques. |
| Consumer Demand | Rising demand for minimally invasive cancer diagnostics and treatment monitoring. |
| Market Growth Drivers | Growth fueled by rising cancer prevalence, investments in precision medicine, and advancements in sequencing. |
| Sustainability | Initial steps toward eco-friendly laboratory practices and digital data storage for reduced paper waste. |
| Supply Chain Dynamics | Dependence on specialized laboratories and centralized testing facilities. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Expanded regulatory support for multi-cancer early detection (MCED) tests and liquid biopsy use in non-oncology applications. |
| Technological Advancements | AI-powered liquid biopsy diagnostics, integration with multi-omics (genomics, proteomics, epigenomics), and single-cell analysis. |
| Consumer Demand | Increased use of liquid biopsy for early disease screening, transplant rejection monitoring, and neurological disorders. |
| Market Growth Drivers | Expansion into new disease areas, wider clinical adoption due to cost reduction, and improved regulatory frameworks. |
| Sustainability | Widespread adoption of green lab technologies, biodegradable reagents, and energy-efficient sequencing processes. |
| Supply Chain Dynamics | Expansion of point-of-care liquid biopsy testing and integration into decentralized healthcare models. |
Market Outlook
The liquid biopsy market in the United States is experiencing robust growth, driven by the increasing prevalence of cancer and a shift towards minimally invasive diagnostic procedures. Advancements in technology, such as next-generation sequencing (NGS), have enhanced the accuracy and efficiency of liquid biopsies, making them a preferred choice for early cancer detection and monitoring. The integration of artificial intelligence (AI) in data analysis further propels market expansion.
Market Growth Factors
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 4.4% |
Market Overview
The growth of China's liquid biopsy market will be rapid, and this is because of a vast patient population and increasing healthcare investment. Initiatives by the government to improve cancer diagnostics and treatment accessibility will further stoke the market. The uptake of liquid biopsy will also find support in the availability of low-cost testing and boosting healthcare infrastructure.
Market Growth Factors
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 7.5% |
Market Outlook
The Indian liquid biopsy market is swiftly on the rise, fueled by an increasing incidence of cancer and the growing awareness regarding early diagnosis. The presence of low-cost testing methods and healthcare programs initiated by the government have positively impacted the market. The other favorable development encouraging wider access to diagnostic services through telemedicine and other digital health platforms is an increasing uptake of these services.
Market Growth Factors
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 8.1% |
Market Outlook
Germany's liquid biopsy market is characterized by advanced healthcare infrastructure and a strong focus on research and development. The country's commitment to precision medicine and personalized healthcare drives the adoption of innovative diagnostic tools like liquid biopsies. Collaborations between research institutions and biotech companies further accelerate market growth.
Market Growth Factors
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 5.6% |
Outlook for the Market
In Brazil, the liquid biopsy industry relies on the evolution of healthcare infrastructure and awareness related to the early detection of cancer. The efforts of the government aimed at expanding healthcare services and investing in introducing advanced technological diagnostic tools to accelerate market growth. But apart from this, regional inequality in access and socioeconomic limitations challenge the development of the market.
Market Growth Factors
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 5.9% |
Circulating tumor nucleic acids (ctNA) have been the leaders in the liquid biopsy market because of their high sensitivity and specificity in detecting cancer
Circulating tumor-related nucleic acids (ctNA) are important biomarkers for tumor diagnosis, monitoring treatment outcomes, and potentially for tumor early detection. ctNA enables noninvasive monitoring of tumor evolution, mutation detection, and targeting therapies.
Some of the market drivers include the expanding trend toward precision oncology, growing FDA approvals of ctDNA tests, and technological advances in next-generation sequencing (NGS) for liquid biopsy. ctNA is predominantly implemented in North America and Europe, whereas the rest of Asia-Pacific countries are growing quickly on the basis of matured investment in tumor screening programs and molecular diagnostics.
Amongst the anticipated innovations are AI-driven ctNA analysis for on-time observation of tumor progression, methylation-based ctDNA detection for oncogenic lesions of early cancer, and multi-omic liquid biopsy platforms that combine ctNA with other biomarkers.
Circulating Tumor Cells (CTCs) Dominated the Liquid Biopsy Market due to its accuracy and clinical applicability
CTCs act as vital biomarkers for the detection of metastatic cancer and prognosis, indicating tumor development, therapy amelioration, and recurrence risk. CTCs have proven effective in the management of breast, prostate, and lung carcinoma, offering oncologists a way to evaluate real-time therapeutic responsiveness and monitor resistance mechanisms.
These three characteristics consider the growing utility clinical enumeration of CTCs has along with increasing amounts of intense research into CTC molecular profiling for tailored therapies and advancements in microfluidic CTC capture technologies. North America and Europe use CTCs in liquid biopsy applications; however, the Asia-Pacific region is rapidly increasing due to rising investments in oncology research. The future will entail AI-enabled CTC phenotyping for precision medicine, single-cell sequencing integration with CTC analysis, and CTC-based tool creation for immunotherapy response monitoring.
Blood-Based Liquid Biopsies Reduce Patient Discomfort and Eliminate the Risks of Surgical Procedures, Making Them the Preferred Choice for Routine Cancer Monitoring.
The blood-based liquid biopsy is a formalized and widely endorsed type of sample-collection in clinical practice. This type of sample collection is considered to be the least invasive method of detecting cancers, monitoring treatment response, and predicting recurrences as compared to conventional tissue biopsies.
Not only does it allow one to do away with painful and mayor surgical operations for obtaining tumor tissues, blood samples provide multiple other biomarkers into ct DNA, CTCs, and exosomes, enabling comprehensive tumor profiling. The factors motivating market growth are the non-invasive cancer diagnostics demand, increasing regulatory approvals of blood-based liquid biopsy tests, and greater adopters for liquid biopsy cases in drugs and clinical trials.
North America and Europe are the highest adopters of blood-based liquid biopsy with Asia-Pacific also gaining ground as it boasts fewer cancer cases and government-initiated campaigns in precision medicine. Future innovations include AI-enabled real-time blood-based cancer screening, MCED liquid biopsy panels for broad-spectrum cancer early detection, and AI-based integration of liquid biopsy data with radiomics to enhance diagnosis.
Plasma-based assays detect minute levels of tumor-derived genetic material, enabling early cancer diagnosis and minimal residual disease.
Plasma liquid biopsy is rapidly becoming a reliable platform for higher sensitivity and specificity methods for the detection of ctDNA and other tumor-derived markers relative to whole has blood. Plasma-based tests are commonly used in lung, colorectal, and breast cancer diagnoses and treatment monitoring, especially when a tissue biopsy cannot be performed.
Advances include the increasing incorporation of plasma-based liquid biopsy in oncology clinical guidelines, increasing development of plasma-derived multifunctional, multi-cancer detection assays, and rising investments in NGS-based plasma biomarker research.
North America and Europe have led plasma-based biopsy research and clinical adoption, while increasing commercialization of these early cancer detection tests is happening in Asia-Pacific. Trends to watch include AI-driven discovery of plasma biomarkers, next-generation epigenetic plasma-based assays, and integration of plasma liquid biopsy with AI-powered digital pathology.
The tremendous growth of the liquid biopsy market is taking place under circumstances of intense competition, triggered by the growing incidence of acceptance for non-invasive cancer diagnostics, further progress in the refinement of ctDNA analysis, and increasing applications in early cancer detection and treatment monitoring.
For competitive advantages, companies are putting their investments into next-generation sequencing (NGS) based liquid biopsy assays, platforms for the detection of multiple cancers, and AI-based biomarker analysis. This market is mostly shaped by well-established diagnostic players, biotechnology innovators, and precision medicine companies that slowly change the landscape of liquid biopsy solutions.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Guardant Health | 22-26% |
| Illumina, Inc. | 18-22% |
| Bio-Rad Laboratories | 10-14% |
| Roche Diagnostics | 8-12% |
| Natera, Inc. | 5-9% |
| Other Companies (combined) | 25-35% |
| Company Name | Key Offerings/Activities |
|---|---|
| Guardant Health | Market leader offering Guardant360, a comprehensive ctDNA-based liquid biopsy test for cancer profiling. |
| Illumina, Inc. | Develops NGS-based liquid biopsy solutions enabling multi-cancer early detection and genomic analysis. |
| Bio-Rad Laboratories | Specializes in digital PCR technology for highly sensitive detection of circulating tumor biomarkers. |
| Roche Diagnostics | Provides advanced liquid biopsy solutions, including Cobas EGFR Mutation Test v2 for lung cancer monitoring. |
| Natera, Inc. | Focuses on personalized liquid biopsy tests such as Signatera for minimal residual disease (MRD) detection. |
Key Company Insights
Guardant Health (22 - 26%)
A dominant in liquid biopsy, the Guardant360 platform by Guardant Health allows for comprehensive cancer profiling with non-invasive procedures, providing guidance for precise treatment decisions and better therapy selections across the various cancer types.
Illumina, Inc. (18 -22%)
The leader in next-generation sequencing technology, Illumina works with high-throughput sequencing applications for liquid biopsy, enabling early cancer detection, minimal residual disease assessment, and real-time tracking of tumor evolution.
Bio-Rad Laboratories (10 - 14%)
An innovator in liquid biopsy by way of digital PCR, Bio-Rad Laboratories concentrates on ultra-sensitive detection of tumor DNA for accurate diagnosis of cancer, monitoring of therapy, and identification of early recurrence with high specificity.
Roche Diagnostics (8 - 12%)
The Roche group is a world leader in oncology diagnostics, provides FDA-approved liquid biopsy assays for monitoring of targeted therapy, companion diagnostics, and personalized treatment strategies for improved clinical outcomes.
Natera, Inc. (5-9%)
A strong contender in personalized oncology, Natera's Signatera test enables highly accurate detection of minimal residual disease (MRD), monitoring of recurrence, and assessment of therapy response by tumor-informed ctDNA analysis.
Other Key Players (25-35% Combined)
Beyond the leading companies, there exist other several players who actually contribute to the market maintaining the product diversification and technology advancement namely:
These companies focus on expanding the reach of liquid biopsy solutions, offering competitive pricing and cutting-edge innovations to meet diverse clinical and research needs.
The global liquid biopsy industry is projected to witness CAGR of 8.4% between 2025 and 2035.
The global Liquid Biopsy industry stood at USD 3,358.8 million in 2024.
The global Liquid Biopsy industry is anticipated to reach USD 19,708.5 million by 2035 end.
India is expected to show a CAGR of 8.1% in the assessment period.
The key players operating in the global Liquid Biopsy industry are Guardant Health, Illumina, Inc., Bio-Rad Laboratories, Roche Diagnostics, Natera, Inc., Exact Sciences Corporation, Foundation Medicine, Thermo Fisher Scientific, NeoGenomics Laboratories, Freenome Holdings and others.
CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes
Blood, Urine and Others
Hospitals, Cancer Institutes, Academic Institutes and Diagnostic Centers
North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa
Liquid Biopsy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
